Melanoma News and Research

Latest Melanoma News and Research

Melanoma patients with high levels of H2A.Z.2 protein less likely to survive

Melanoma patients with high levels of a protein that controls the expression of pro-growth genes are less likely to survive, according to a study led by researchers at Icahn School of Medicine at Mount Sinai and published online in the journal Molecular Cell.

18 Jun 2015

Experts review strategies that may help improve adoptive cell immunotherapy for treating cancer

In a special issue of Immunotherapy, leading experts provide in-depth review of innovative strategies that may further the success of adoptive cell immunotherapy as a cancer treatment. Adoptive cell immunotherapy (ACT) has proven successful in clinical trials against certain types of melanoma and leukemia. The journal reviews new strategies to address the challenges of extending these effects to a wider range of tumor types.

17 Jun 2015

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, announced today that the company has enrolled the first patient into OMS-I130, a Phase II clinical trial of ImmunoPulse IL-12 in patients with treatment-refractory, metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC).

16 Jun 2015

UK dermatologist explains the facts on vitamin D and sun exposure

Sometimes it can be hard to weigh up the benefits of vitamin D versus sun exposure. We talk to Dr Anjali Mahto, Consultant Dermatologist & British Skin Foundation Spokesperson who explains.

16 Jun 2015

EORTC prospective registry targets patients with minimal sentinel node tumor burden in melanoma

Sentinel node biopsy is the standard staging procedure for melanoma patients, and sentinel node status is the most important prognostic factor for disease outcome in AJCC stage I/II disease. However, the therapeutic value of the sentinel node procedure followed by early completion lymph node dissection is still controversial.

15 Jun 2015

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor, Weill Cornell Medical College scientists report today. But a therapy that restores the cells' disease-fighting abilities could provide a powerful new strategy to attack the cancer, which kills more than 14,000 women each year.

12 Jun 2015

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced the U.S. Patent & Trademark Office has issued a Notice of Allowance to the Company for an important manufacturing method patent for its drug candidate CF101.

10 Jun 2015

GSU scientists design new MRI technique for early detection of liver tumors

Scientists at Georgia State University with funding from the National Institute of Biomedical Imaging and Bioengineering have designed an imaging technique to detect early-stage liver tumors, and have proven it successful in mice.

10 Jun 2015

UT Southwestern researchers reveal how the body controls glucose transport

UT Southwestern Medical Center scientists have gleaned a key cellular mechanism of how the body adjusts glucose levels, an important process that when abnormal can promote diabetes, cancer, and rare genetic diseases.

10 Jun 2015

OncoSec Medical reports net loss of $14.7 million for FY 2015

OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the nine months ended April 30, 2015.

9 Jun 2015

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.

8 Jun 2015

EMA, ESMO and RCE joint workshop focuses on rare cancers and chordoma

To date, there is no drug approved for medical therapy of chordoma patients. Supporting research for chordoma (a very rare cancer arising from the skull base or the spine and affecting only one person in a million per year) was the focus of talks that took place on 30 April 2015 at the European Medicines Agency in London. The workshop was attended by patients, oncologists, pathologists, regulators, statisticians and industry representatives.

4 Jun 2015

Researchers developing probe wire to better understand causes of degenerative brain diseases

Researchers are developing a tiny wire that will speed up the discovery of new drugs and could one day unlock the mysteries of illnesses such as Alzheimer's or Lou Gehrig's disease.

4 Jun 2015

RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd‑rxRNA).

3 Jun 2015

UC Santa Cruz-led study offers new insights into molecular mechanisms of biological clock

A new study led by UC Santa Cruz researchers has found that a protein associated with cancer cells is a powerful suppressor of the biological clock that drives the daily ("circadian") rhythms of cells throughout the body.

3 Jun 2015

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

Two phase III trials published in The New England Journal of Medicine support the use of nivolumab in patients with treatment-naïve metastatic melanoma and in those with squamous non-small-cell lung cancer who have failed first-line chemotherapy.

2 Jun 2015

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Results of two clinical trials reported at the American Society for Clinical Oncology Annual Meeting 2015 show continued promise of immune therapies nivolumab and pembrolizumab against advanced melanomas, specifically in the context of PD1 signaling that some tumors use to avoid immune system attack. Dr. Rene Gonzalez, MD, investigator at the University of Colorado Cancer Center and director of the Melanoma Research Clinics at the CU School of Health, is an author of both studies.

2 Jun 2015

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, over the weekend in Chicago released promising new data on their Phase I trial of DCVax-Direct for direct injection into all types of inoperable solid tumors.

2 Jun 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.

2 Jun 2015

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

DNA Therapeutics, a private biopharmaceutical company developing DT01, a first-in-class clinical pan DNA repair inhibitor to treat tumors resistant to conventional treatments, will today present the results of the first-in-man phase 1/2a trial of DT01 in combination with radiation therapy in patients with cutaneous metastatic melanoma.

2 Jun 2015

Melanoma News and Research

Latest Melanoma News and Research

Melanoma patients with high levels of H2A.Z.2 protein less likely to survive

Experts review strategies that may help improve adoptive cell immunotherapy for treating cancer

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

UK dermatologist explains the facts on vitamin D and sun exposure

EORTC prospective registry targets patients with minimal sentinel node tumor burden in melanoma

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

GSU scientists design new MRI technique for early detection of liver tumors

UT Southwestern researchers reveal how the body controls glucose transport

OncoSec Medical reports net loss of $14.7 million for FY 2015

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

EMA, ESMO and RCE joint workshop focuses on rare cancers and chordoma

Researchers developing probe wire to better understand causes of degenerative brain diseases

RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

UC Santa Cruz-led study offers new insights into molecular mechanisms of biological clock

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in